The Cheap Investor Exclusive

The Market Is Wrong About Cigna

Hey there, bargain hunter.

Let me ask you something. What do you do when a company beats earnings estimates for the fourth consecutive quarter, raises its full-year guidance, grows adjusted EPS by 16% year over year, and posts revenue of $68.5 billion against a forecast of $66.2 billion?

If you’re most investors right now, apparently you sell the stock anyway.

That’s exactly what happened with The Cigna Group (NYSE: CI) after its Q1 2026 results dropped on April 30. Beat on EPS. Beat on revenue. Guidance raised. Stock fell roughly 3% in pre-market trading. The market essentially shrugged and moved on.

This is the kind of disconnect that gets a value investor’s attention.

What Actually Happened

Cigna is not a broken company. Far from it. The numbers say otherwise quite clearly.

Q1 2026 adjusted EPS came in at $7.79, up 16% year over year. Revenue hit $68.5 billion, topping estimates by 3.5%. Management lifted full-year 2026 adjusted EPS guidance to at least $30.35. Evernorth, the company’s health services engine, generated $58.4 billion in revenue, up 9% year over year. Specialty and Care Services earnings jumped 20% to $1.1 billion. The medical care ratio within Cigna Healthcare improved to 79.8%.

That is not the financial profile of a company in trouble. That is a company executing well in a tough environment.

And yet the stock sits roughly 19% below its 52-week high. The forward P/E is somewhere around 8 to 9 times earnings. At roughly 12x trailing earnings, Cigna trades at less than half the healthcare industry average of about 26x and well below the peer average of 44x. A PEG ratio near 0.16 suggests the market is barely pricing in any of Cigna’s growth at all.

Why the Whole Sector Got Punished

Here’s the thing. Cigna’s discount is not primarily a Cigna story. It’s a managed care story. And managed care has been one of the most out-of-favor corners of the entire market for going on two years.

The selloff started with real problems: rising medical utilization costs, companies that prioritized enrollment growth over profitability, and insurance premiums that failed to keep pace with claims. Then in January 2026, the Centers for Medicare and Medicaid Services proposed keeping Medicare Advantage rates nearly flat for 2027, well below the 4% to 6% increase analysts had expected. Managed care stocks cratered. The sector’s market cap as a share of the broader healthcare index fell to its lowest level since 2009, roughly 6%, down from more than 14% just a few years ago.

Slight tangent: this kind of sector-wide compression is actually where the most interesting value situations tend to emerge. When a whole group gets punished, the market stops distinguishing between the weak players and the strong ones. Everything trades down together. The question then becomes which businesses deserve to recover, and which were just dragged along for the ride.

Cigna fits the first category. Its problems are largely structural transitions being managed with discipline, not fundamental deterioration. The company is exiting Medicare Advantage and the individual ACA exchange business, two segments with persistent margin pressure. It is also undertaking a strategic review of EviCore. These moves are creating near-term noise in the financials, but they are arguably the right decisions for long-term profitability.

What Cigna Actually Is

Cigna operates across two main segments. The first is Evernorth Health Services, which handles pharmacy benefit management, specialty pharmacy, and care services. This is the growth engine. The second is Cigna Healthcare, which covers traditional health insurance for employers, government programs, and international markets.

The business that most people associate with Cigna, the health insurance piece, is actually the smaller driver today. Evernorth generated roughly 85% of total revenues in Q1 2026. That is a meaningful shift. Cigna has been repositioning itself as a health services company rather than a pure-play insurer, and the specialty pharmacy and biosimilar businesses within Evernorth are growing fast. Specialty and Care Services earnings were up 20% in the most recent quarter, driven by biosimilar and specialty generic adoption.

The company’s new rebate-free pharmacy model, called Signature, is designed to pass drug cost savings directly to consumers. This is a significant strategic bet on transparency in the pharmacy benefits business, which faces increasing regulatory scrutiny of its traditional rebate practices. If the model works, it could become a competitive differentiator. If it doesn’t, it compresses margins in the near term with nothing to show for it. That is the central risk here.

The Numbers That Matter

• Q1 2026 Revenue: $68.5 billion (beat estimate of $66.2 billion by 3.5%)
• Q1 2026 Adjusted EPS: $7.79 (beat estimate of $7.61 by 2.4%)
• Year-over-year adjusted EPS growth: 16%
• Full-year 2026 adjusted EPS guidance: at least $30.35
• Evernorth revenues: $58.4 billion, up 9% year over year
• Specialty and Care Services earnings: $1.1 billion, up 20%
• Cigna Healthcare medical care ratio: 79.8%
• Consecutive quarters of beating both EPS and revenue estimates: 4
• 52-week price range: approximately $244 to $339
• Forward P/E: approximately 8 to 9x (as of mid-July 2026)
• Trailing P/E: approximately 12x, versus healthcare sector average of roughly 26x
• Analyst consensus: Strong Buy from 23 analysts in coverage
• Average analyst price target: approximately $340 to $343, roughly 20% to 25% above current levels

Is It Cheap, Fairly Valued, or a Trap?

This is always the hardest question. A low P/E means nothing if the E is about to collapse.

For Cigna, the bear case centers on a few legitimate concerns. Regulatory scrutiny of pharmacy benefit managers is intensifying. The transition to a rebate-free model is compressing near-term Pharmacy Benefit Services earnings, which fell 28% in Q1. The company is exiting large segments of its business, creating comparability issues and execution risk. And a new CEO, Brian Evanko, takes the helm at a genuinely complex moment for the organization.

The bull case is simpler. The business is profitable, growing, and beating estimates consistently. The core Evernorth franchise is structurally advantaged by scale in specialty pharmacy, a market that is growing rapidly as biosimilar adoption accelerates. The valuation already prices in a lot of bad news. At 8 to 9 times forward earnings, investors are paying almost nothing for a business generating more than $30 in earnings per share annually, with a management team that has now raised guidance after two consecutive quarters of strong execution.

What’s interesting is that the managed care group as a whole has already begun recovering from its March 2026 lows. According to Janus Henderson, the S&P 1500 Managed Health Care sub-industry rose more than 50% from its end-of-March trough through mid-year, driven by greater visibility around federal reimbursement and improved Medicare Advantage rate decisions. Cigna has lagged that recovery meaningfully, which suggests either that the market sees company-specific risk others have cleared, or that it simply has not caught up yet.

Our read: this looks more like opportunity than trap, but it is not a zero-risk situation. The Evernorth transition is real, the regulatory backdrop is genuinely uncertain, and investors should expect continued volatility around Q2 2026 results scheduled for July 30.

Bull, Base, and Bear

• Bull: Evernorth specialty and biosimilar businesses accelerate into the second half of 2026. Signature pharmacy model gains adoption and proves margin-accretive within 12 to 18 months. Regulatory clarity on PBM practices arrives and removes the sector overhang. Stock re-rates toward peer valuations, implying potential upside of 30% or more from current levels.
• Base: Cigna delivers on its raised 2026 guidance of at least $30.35 adjusted EPS, stock trades in the $310 to $340 range by year-end as sentiment gradually improves toward managed care. Modest multiple expansion from an extremely depressed base.
• Bear: Pharmacy Benefit Services earnings deteriorate further as large client relationships shift. The Signature model fails to attract meaningful volume, compressing margins with no offsetting revenue. Regulatory action on PBMs introduces structural earnings headwinds. Stock remains range-bound or drifts lower despite decent earnings.

Cheap Investor Scorecard

Action Plan for Patient Investors

If the thesis resonates, here is how a disciplined value investor might approach it.

Watch Q2 2026 results closely on July 30. The question is not whether Cigna hits its number; it probably will. The question is whether Pharmacy Benefit Services earnings show any stabilization, and whether Signature is gaining traction with clients. Those two data points matter more than the headline EPS beat.

If results confirm the trend, consider a starter position. Valuation provides meaningful cover here. You’re not paying a premium for perfection. You’re paying a discounted price for a business with genuine competitive advantages in a sector that the market has broadly abandoned.

If Pharmacy Benefit Services deteriorates further, or if the company signals that the Signature model is struggling with adoption, that changes the calculus. The near-term earnings story could get messier before it gets cleaner.

The bottom line on Cigna is conditional. If Evernorth continues to grow, if specialty and biosimilar volumes hold, and if the managed care sector’s broader recovery continues, then CI at roughly 8 to 9 times forward earnings looks like a meaningful disconnect between price and fundamental value. If the regulatory picture darkens further and PBM reform legislation accelerates, the current discount could be partially warranted.

What the market appears to be doing right now is treating all of Cigna’s challenges as permanent when several of them look temporary or at least manageable. That is exactly the kind of perception gap this publication exists to examine.

Keep watching. July 30 is the next real data point.

This editorial is for informational and educational purposes only. It does not constitute individual investment advice. All data sourced from company filings, analyst reports, and publicly available financial data as of mid-July 2026. Verify all figures independently before making any investment decision.